HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,009,634 | -16.3% | 265,578 | -2.8% | 0.23% | -6.1% |
| Q2 2023 | $11,956,787 | +11.2% | 273,298 | -2.9% | 0.24% | +11.9% |
| Q1 2023 | $10,748,461 | -33.7% | 281,447 | -1.2% | 0.22% | -34.1% |
| Q4 2022 | $16,201,934 | +36.8% | 284,744 | -4.9% | 0.33% | +34.6% |
| Q3 2022 | $11,843,000 | -10.1% | 299,528 | +0.0% | 0.25% | -5.7% |
| Q2 2022 | $13,175,000 | +13.3% | 299,434 | +2.7% | 0.26% | +40.3% |
| Q1 2022 | $11,626,000 | -0.9% | 291,520 | -0.1% | 0.19% | +9.4% |
| Q4 2021 | $11,737,000 | -3.3% | 291,899 | -2.2% | 0.17% | -6.1% |
| Q3 2021 | $12,141,000 | -13.9% | 298,454 | -3.9% | 0.18% | -13.8% |
| Q2 2021 | $14,109,000 | +0.5% | 310,692 | -7.7% | 0.21% | -0.5% |
| Q1 2021 | $14,039,000 | +8.7% | 336,754 | +11.3% | 0.21% | -11.0% |
| Q4 2020 | $12,920,000 | +67.3% | 302,503 | +2.9% | 0.24% | +38.6% |
| Q3 2020 | $7,724,000 | +20.4% | 293,903 | +22.9% | 0.17% | +11.8% |
| Q2 2020 | $6,413,000 | – | 239,194 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |